Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
My Lists

Satsuma Pharmaceuticals  (Stock symbol: STSA )

400 Oyster Point Boulevard Suite 221
South San Francisco, CA 94080
Website Company Summary Management Team

CEO: John Kollins (6/30/2016)
President/COO/Operations: Mic Iwashima
General Management: Shannon Storm (5/31/2018) ; Detlef Albrecht (6/30/2017)
Finance: Thomas P O'Neil (1/31/2019)

Outside board: (May no longer be on the board) Heath Lukatch (TPG Biotech Partner & Managing Director) Rajeev Shah (RA Capital Managing Director) Ken Takanashi (Shin Nippon Biomedical Laboratories)

Business description: Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing STS101 as an important and differentiated therapeutic option for the acute treatment of migraine. STS101 is a novel and proprietary investigational drug-device combination product specifically designed to enable intranasal administration of the anti-migraine drug, dihydroergotamine (DHE), with a pharmacokinetic profile optimized to provide consistent and robust clinical efficacy. In developing STS101, Satsuma has applied proprietary nasal drug delivery, dry-powder formulation, and engineered drug particle technologies to create a compact, simple-to-use, self-administered, and non-injectable DHE product. The Company believes STS101 will be an attractive migraine treatment option for many patients and may enable a larger number of people with migraine to realize the long-recognized therapeutic benefits of DHE therapy. STS101 has undergone extensive pre-clinical optimization and recently completed a Phase 1 clinical trial. Satsuma is headquartered in South San Francisco, California with operations in both California and Research Triangle Park, North Carolina.

Rounds: 2
Recent Fundings: Apr 2019   Jan 2017
Capital raised: 74.0M
Last Round: 62.0M
Ownership: Public   Ipo Filing
Stock Symbol: STSA
VCs include: SBI Investment TPG Biotech ;  Osage University Partners ;  RA Capital Management Wellington Management Company ;  Shin Nippon Biomedical Laboratories ;  CAM Capital Lumira Ventures
Private equity: Eventide Asset Management
Other investors: Cormorant ;  Surveyor

Last Tweets


Last Mentions

Record updated: Jul 2022
Sector: Medical
Year Founded: 2016
Headcount: 26-50 as of Jul 2022
Rounds: 2
Recent Fundings: Apr 2019   Jan 2017
Capital Raised: 74.0M
Last Round: 62.0M
Ownership: Public   Ipo Filing
Stock Symbol: STSA